

**DEPARTMENT OF HEALTH AND HUMAN SERVICES  
FOOD AND DRUG ADMINISTRATION  
CENTER FOR DRUG EVALUATION AND RESEARCH**

**CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE  
96<sup>th</sup> Meeting  
April 12, 2002**

**Holiday Inn, Silver Spring, MD**

**NDA 20-386/S028, Cozaar™ (losartan potassium), Merck and Company, Inc.  
Proposed Indication: for the treatment of type II diabetic patients with nephropathy**

**Special Government Employees/Consultants (voting)**

Jeffrey B. Kopp, M.D.  
Senior Investigator  
Kidney Disease Section, Metabolic Diseases Branch  
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)  
National Institutes of Health (NIH)  
Bldg. 10, Rm. 3N116  
Bethesda, MD 20892-1268

Andrew S. Brem, M.D.  
Professor in Pediatrics  
Brown University School of Medicine  
Director, Division of Pediatric Nephrology  
Rhode Island Hospital  
593 Eddy Street  
Providence, RI 02902